{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-090702","form_type":"8-K/A","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.617266+00:00","generated_at":"2026-06-11T12:34:15.422291+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma reports H1 2023 net loss of $33M; cash at $2.6M with going-concern doubt","bullets":["Net loss of $33.0M for six months ended June 30, 2023 vs $7.6M loss in H1 2022.","Cash fell to $2.6M as of June 30, 2023 from $9.7M at Dec 31, 2022.","Accumulated deficit reached $507.9M; auditor notes substantial doubt about going concern.","Convertible notes total $134.4M ($73.4M current + $60.9M non-current) as of June 30, 2023.","Business combination with Priveterra closed July 21, 2023; now listed on NYSE as AEON."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-090702","json":"https://secwatch.observer/filing/0001104659-23-090702.json","markdown":"https://secwatch.observer/filing/0001104659-23-090702.md","text":"https://secwatch.observer/filing/0001104659-23-090702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923090702/0001104659-23-090702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923090702/tm2323141d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:34:15.422291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}